In particular, plasma LCN2 was found to be negatively corrected with clinical dementia rating scores and positively corrected with mini-mental status examination scores, and is therefore regarded as a potential marker to predict the progression from mild cognitive impairment to AD (Choi et al., 2011; Naude et al., 2012). This evidence concerns the gene LCN2 and Alzheimer disease.